Medicare GLP-1 Cost-Neutrality Analysis: MFN Pricing Still Falls Short by ~$18B
A University of Chicago analysis published in JAMA Network Open (May 2026) modeled the 10-year budget impact of expanding Medicare GLP-1 coverage under the new Most Favored Nation (MFN) pricing framework.
Key Findings
- MFN price set at $245/month for GLP-1 drugs when prescribed for weight management — far below prior US list prices that often exceeded $1,000/month
- Under expanded coverage to ~30 million Medicare beneficiaries with obesity (without diabetes or CVD), the model projects:
- ~$74 billion in 10-year drug costs
- ~$56 billion in downstream health savings (reduced diabetes, heart disease, complications)
- Net ~$18 billion in additional Medicare spending over 10 years
- The $245 price includes a $50 monthly copay, meaning actual Medicare cost is $195/month — close to the cost-neutrality point of $185/month calculated by the researchers
Key Assumptions
- 30% of newly eligible patients start therapy
- 40% of starters remain on treatment long-term
- Semaglutide patent expiry expected around 2032, which could bring substantial price reductions
Policy Implications
The researchers flagged that most of the remaining cost sits in the long-term maintenance phase and called for innovative weight-maintenance strategies1 (alternative dosing, lower-cost drugs, behavioral interventions) to close the gap. The near-cost-neutrality at current pricing strengthens the case for broader coverage by Medicare, Medicaid, and private insurers.
-
An instance of The state must directly underwrite massive obesity drug liabilities when private insurers refuse the risk. — Despite negotiated state pricing, the immense burden of long-term obesity treatment still leaves a massive, un-offset deficit for the government to absorb. ↩︎